Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients ...Middle East

The VENTANA HER2 (4B5) test is now CE-IVDR approved to aid in the assessment of HER2-ultralow status to identify metastatic breast cancer patients who may be eligible for treatment with ENHERTU. The VENTANA HER2 (4B5) test is also now approved to help identify patients with...

Hence then, the article about roche receives ce ivdr approval for her2 4b5 companion diagnostic test to identify her2 ultralow breast cancer and biliary tract cancer patients was published today ( Friday 05/09/2025 - 08:13 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients )

Also on site :

• Germany’s Merz changes stance on Russia
• Tokyo's Yamanote Line suspended due to power outage
• Tokyo's Yamanote loop line trains out of service due to power outage